Key result
Frailty is linked to ~91% higher mortality and attenuates the prognostic impact of multimorbidity.
Why the study?
The modification effect of frailty on the prognostic association of multimorbidity in heart failure patients was unclear.
Does frailty modify the prognostic value of multimorbidity on all-cause mortality in patients with heart failure?
Cohort (n=18,058)
No
Does frailty modify the prognostic value of multimorbidity on all-cause mortality in patients with heart failure?
Hazard Ratio: 1.91 (95% CI 1.85–2)
Frailty attenuates the prognostic value of multimorbidity in heart failure, indicating that multimorbidity primarily stratifies mortality risk in patients with preserved physiological reserve.
OBJECTIVE To evaluate whether frailty modifies the association of multimorbidity in HF. METHODS A retrospective cohort study of HF patients. Multimorbidity was quantified using 26 conditions and categorized as low (≤4), intermediate (5-7), or high (>8). Frailty was defined using a multimodal construct integrating functional, nutritional, and biochemical domains. All-cause mortality was assessed using cox models with frailty-multimorbidity interaction testing. Charlson Comorbidity Index (CCI) was used for validation. RESULTS Among 18,058 patients (median age 74 years; 62% male; 64% frail), 57% died over a median follow-up of 4.0 years (IQR 1.3-7.7). Multimorbidity burden comprised 30.5% low, 48% intermediate, and 21.5% high. Frailty was associated with a 91% higher mortality risk (adjusted HR 1.91; 95% CI 1.85-2.00). Compared with low multimorbidity, intermediate and high burden were associated with an independent 8% and 20% higher mortality risks, respectively (95% CI 1.02-1.14 and 1.13-1.27; both p<.001). However, the association of multimorbidity differed by frailty such that among non-frail patients, intermediate and high multimorbidity increased mortality by 18% and 42% whereas in frail patients, the association was attenuated, with no excess risk for intermediate burden and only 13% increase for high burden (p-for-interaction <.001). CCI analyses was consistent, though differed among females and HFpEF. CONCLUSION Frailty fundamentally attenuates risk in HF, while multimorbidity stratifies prognosis only when physiological reserve is preserved.
No takes yet. Share an insight, caveat, or question.
Copeland et al. (2026) conducted a cohort in Heart Failure (n=18,058). Frailty vs. Non-frail patients was evaluated on All-cause mortality (HR 1.91, 95% CI 1.85-2.00). Frailty was associated with higher all-cause mortality (HR 1.91; 95% CI 1.85-2.00) and significantly attenuated the prognostic impact of multimorbidity (P-for-interaction <0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: